Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV.
Arianna E KousariMelissa P WilsonKellie L HawkinsMohamed Mehdi BandaliAndrés F Henao-MartínezEdward M GardnerKristine M ErlandsonPublished in: HIV research & clinical practice (2024)
Overall, modest changes in weight were seen following ART switch from INSTI-based regimen to a DOR-based, non-INSTI regimen. Further investigations with larger people with HIV cohorts will be helpful to guide clinical practice, while the impact of the COVID-19 pandemic on weight change should also be considered.